| Original language | English (US) |
|---|---|
| Pages (from-to) | 1181-1182 |
| Number of pages | 2 |
| Journal | JAMA cardiology |
| Volume | 2 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2017 |
Funding
completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Bonow served as chair of the DSMB of LIBERTY HCM Trial, sponsored by Gilead Sciences, discontinued in 2016, the Gilead Sciences Clinical Scholars Program in Cardiovascular Disease, 2010-2015, and currently serves on the DSMB of the COBRA PzF SHIELD trial, coordinated by the Baim Clinical Research Institute, sponsored by CeloNova Biosciences, Inc, and the WARRIOR Trial, sponsored by the US Department of Defense. Dr Harrington reports grants and personal fees from Merck and The Medicines Company; grants from CSL, GSK, Sanofi Aventis, AstraZeneca, Portola, Janssen, BMS, Novartis; and personal fees from Amgen, Element Science, Gilead, MyoKardia, WebMD, Scanadu, and Signal Path outside the submitted work. Dr Harrington is on the Board of Directors (nonpaid) for American Heart Association and for Stanford HealthCare. No other disclosures were reported.
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine